- 米国企業
- C4 Therapeutics, Inc.
C4 Therapeutics, Inc.CCCC
時価総額
$4億
PER
2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | |
Revenue from collaboration agreements | - | - | 31 | 21 |
Research and development | 78 | 95 | 118 | 118 |
General and administrative | 15 | 33 | 43 | 42 |
Total operating expenses | 94 | 128 | 161 | 160 |
Loss from operations | -60 | -82 | -130 | -139 |
Interest expense and amortization of long-term debt—related party | - | - | 2 | 1 |
Interest and Other Income | 0 | 0 | 4 | 10 |
Loss on early extinguishment of debt | - | - | - | -1 |
Total other income (expense), net | -7 | -2 | 1 | 8 |
Interest and Other Income | 0 | 0 | 4 | 10 |
Total other income (expense), net | -7 | -2 | 1 | 8 |
Net loss | -66 | -84 | -128 | -132 |
Loss before income taxes | -67 | -84 | - | -131 |
Earnings Per Share, Basic | - | - | -2.62 | -2.67 |
Income tax expense | -1 | - | - | 1 |
Earnings Per Share, Diluted | - | - | -2.62 | -2.67 |
Net loss | -66 | -84 | -128 | -132 |
Earnings Per Share, Basic | - | - | -2.62 | -2.67 |
Earnings Per Share, Diluted | - | - | -2.62 | -2.67 |
Marketable Security, Unrealized Gain (Loss) | 0 | -1 | -3 | 4 |
Comprehensive loss | -66 | -85 | -132 | -128 |
Marketable Security, Unrealized Gain (Loss) | 0 | -1 | -3 | 4 |
Comprehensive loss | -66 | -85 | -132 | -128 |